CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients

Autoantibody-producing plasma cells are frequently resistant to conventional immunosuppressive treatments and B-cell depletion therapy. As a result of this resistance, autoreactive plasma cells survive conventional therapy, resulting in persistent autoantibody production and inflammation. CD38 is hi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Transl Autoimmun
Autores principales: Frerichs, Kristine A., Verkleij, Christie P.M., Bosman, Patricia W.C., Zweegman, Sonja, Otten, Henny, van de Donk, Niels W.C.J.
Formato: Artigo
Lenguaje:Inglês
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7388400/
https://ncbi.nlm.nih.gov/pubmed/32743508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtauto.2019.100022
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares